contact us krjpencn

뉴스현황

Our Events

현재 위치: > 뉴스현황 > Our Events > Medicilon has Won Pr...

Medicilon has Won Praises and Awards From Multiple Partners Again

저자:Medicilon   업로드:2022-03-02  조회수:

Is there no industry precedent for first-in-class innovative drugs? Then be a precedent.  No successful experience to learn from? Then create experience.
PROTAC drug development is facing difficulties and challenges? Then conquer them one by one and make it possible…

Once again, Medicilon has overcome technical problems in R&D, delivered more than expected “answer sheets”, promoted the progress of projects efficiently, and increased collaboration efforts.  Medicilon has won the trust and awards of clients with their strength and hard work:

In the past year, Medicilon has fulfilled the service commitment to clients with actions and results, “Innovation Driven, Quality First.”  These honors are the best testimony.

The pharmaceutical industry is surging, and Medicilon has always maintained innovation.  In fact, Medicilon has been in the pharmaceutical industry for 18 years, and has already integrated its innovative genes into the research and development.
The PROTAC innovative drug project of LeadingTac Pharma is a first-in-class R&D project for anti-tumor and autoimmune diseases.  In the collaboration with Medicilon, the Medicilon DMPK team actively communicated with LeadingTac and gave full support.  In the absence of experience and successful cases in the industry, Medicilon helped LeadingTac to solve a series of R&D problems such as large molecular weight, to ensure the smooth completion of the project.  With regard to this, LeadingTach presented Medicilon with the “The Best Medicinal Chemistry Partner Team Award”, “The Best DMPK Partner Team Award” and “The Best DMPK Partner Individual Award” to affirmed the collaboration with Medicilon.
Also, the Medicilon FTE team also received client awards.  The Medicilon FTE team uses a flexible collaboration model to meet the diverse research and development needs of clients, from target confirmation, compound optimization, compound screening and drugability research to save customers time and cost and to contribute the rapid advancement of the project process.
ABM Therapeutics has collaborated with Medicilon since 2016. During the six-year collaboration, ABM Therapeutics has always been satisfied with the service quality of FTE.  In 2021, Medicilon was awarded the “The Best Service Team Award” from ABM Therapeutics.  During the collaboration, Medicilon FTE also assisted ABM Therapeutics to discover the preclinical candidate compound (PCC) ABM-1310.  (The drug is currently undergoing clinical trials in both China and the United States.)
MindRank AI is an AI pharmaceutical company. In the collaboration Medicilon FTE Team, the advantages of AI design combined with laboratory confirmation have been fully display.  Medicilon completed the collaborative projects with high quality in a short-time, low-cost and efficient work mode.  Therefore, Medicilon was awarded the “2021 Excellent Team Award” by the client.
If innovation is the driving force of Medicilon's progress, then quality is the lifeline that Medicilon adheres to.  Since the establishment, Medicilon has regarded quality as its lifeline and code of conduct.  Whether it is establishing quality management system standards or generalized standards for clients, Medicilon always abides by global quality and regulations, efficiently provides authoritative and high-quality data to shortens the research and development cycle.
In addition to the above-mentioned awards, Medicilon also recently won the “Excellence in Service Award of 2021” by Kumquat Biosciences, “Excellent Performance Award” by Jemincare, “The Best Partner Award” and “The Best Contribution Award” by Regor Therapeutics Group and “The Best Partner Award” by MediLink Therapeutics.
Every glory is inseparable from the support of clients and the efforts of Medicilon.  Medicilon will make unremitting efforts to improve the comprehensive strength, to commit becoming a trusted CRO for biopharmaceutical preclinical comprehensive R&D services, to promote the development of the pharmaceutical industry and is always ready for the challenges.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally.  Medicilon is proud to contribute to human health in the globe.

이전:Medicilon was selected as a constituent stocks of the "STAR 50" Index

다음에:Imbioray Completes 230 million Round A Financing